Xencor, Inc. (NASDAQ:XNCR) Receives $34.38 Average Target Price from Brokerages

Shares of Xencor, Inc. (NASDAQ:XNCR) have been given a consensus rating of “Buy” by the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $34.38.

XNCR has been the subject of a number of recent analyst reports. StockNews.com downgraded Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and increased their price target for the company from $20.00 to $30.00 in a research report on Monday, December 2nd. Finally, Wells Fargo & Company decreased their price objective on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a report on Friday, February 28th.

Institutional Investors Weigh In On Xencor

Hedge funds and other institutional investors have recently bought and sold shares of the business. Sanctuary Advisors LLC purchased a new position in shares of Xencor in the third quarter valued at $540,000. Barclays PLC boosted its stake in Xencor by 100.7% in the 3rd quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company’s stock worth $3,128,000 after purchasing an additional 78,066 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Xencor during the 3rd quarter valued at about $362,000. Jane Street Group LLC increased its position in shares of Xencor by 18.6% during the third quarter. Jane Street Group LLC now owns 168,431 shares of the biopharmaceutical company’s stock valued at $3,387,000 after buying an additional 26,473 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Xencor by 1.2% in the third quarter. Geode Capital Management LLC now owns 1,455,350 shares of the biopharmaceutical company’s stock worth $29,273,000 after buying an additional 17,658 shares in the last quarter.

Xencor Stock Performance

NASDAQ XNCR opened at $10.64 on Tuesday. The company has a fifty day moving average price of $15.39 and a 200-day moving average price of $20.01. The firm has a market cap of $749.72 million, a price-to-earnings ratio of -3.33 and a beta of 0.74. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. Xencor has a 1 year low of $10.40 and a 1 year high of $27.24.

Xencor (NASDAQ:XNCR) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.19. The firm had revenue of $52.79 million for the quarter, compared to analysts’ expectations of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. As a group, equities research analysts predict that Xencor will post -3.68 EPS for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.